N@N

COLORADO SPRINGS, Colo.--([ BUSINESS WIRE ])--Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is excited to announce that it has created the aCannabis Science Research Foundationa. The Cannabis Science Research Foundation is a new source of hope for a world where numerous critical medical conditions affect millions of people in the United States alone, and do not have satisfactory treatment options. This Foundation will be unique in that it is dedicated to bring new findings about the endocannabinoid system and how phytocannabinoids can modulate it's activity with the aim of facilitating the translational work necessary for widespread medical implementation.

The Foundation will be funded internally and externally through donations, and fundraising charity events, such as charity black tie events, fundraising dinner events, concerts, movie showings, documentaries, etc.

The company realizes that in order to bring cannabis-based medications and remedies to the mainstream market, extensive research is necessary. The Foundation will target numerous critical ailments Cannabis Science has identified by working with patients in medical cannabis states. Our patient oriented research helps us in determining appropriate treatments and guides Cannabis Scienceas development of new products for each of the Companyas targeted national and international distribution markets. Of course, all of your efforts move the Company closer to entering the FDA to perform federally approved clinical studies so that medical claims can be justified.

The initial focus of the Foundation will begin with cancer treatment. The Company has already reported the apparent success with self-medicated cancer patients using its formulations on basal and squamous cell carcinomas (please see the website at [ www.cannabisscience.com ] and click on aBreaking Newsa). These findings have spearheaded more cancer research necessary for understanding the influence cannabis can have on the illness. Additional research will be supplemented by the Foundation.

All the funds raised in the Foundation will provide the financial strength to support research efforts, including new developments that will be announced soon.

In addition to research, advocacy and education are fundamental parts of the Foundationas mission. The current conventional medical industry lacks a holistic understanding about the endocannabinoid system and the benefits cannabis has for those who are ill. Through education, the Foundation hopes to change the mainstream view of cannabis and create a standard for developing safe, effective medications that will be the model for what cannabis medicine can be. The foundationas board of directors, currently being assembled, will bring together experience and knowledge in the relevant scientific, financial, regulatory and political fields of medical cannabis. The Cannabis Science Research Foundation hopes that you will follow and contribute to our development by coming on board and donating to this exciting and much needed cause.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.